{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Hormone+Treatment", "query": { "condition": "Growth Hormone Treatment" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 163, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Hormone+Treatment&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T07:40:40.089Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03725059", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab (K)", "type": "BIOLOGICAL" }, { "name": "Placebo (P)", "type": "DRUG" }, { "name": "Paclitaxel (X)", "type": "DRUG" }, { "name": "Doxorubicin (A)", "type": "DRUG" }, { "name": "Epirubicin (E)", "type": "DRUG" }, { "name": "Cyclophosphamide (C)", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1240, "start_date": "2018-12-27", "completion_date": "2031-01-24", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 45, "location_summary": "Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03725059" }, { "nct_id": "NCT02069093", "title": "Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Dexamethasone based mouthwash", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2014-05", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-02-13", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 23, "location_summary": "Fayetteville, Arkansas • Anaheim, California • Los Angeles, California + 17 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02069093" }, { "nct_id": "NCT04938466", "title": "Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Growth Hormone Deficiency", "Growth Hormone Treatment" ], "interventions": [ { "name": "Long-Acting Growth Hormone (LAGH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "13 Years", "sex": "ALL", "summary": "2 Years to 13 Years" }, "enrollment_count": 19, "start_date": "2021-08-05", "completion_date": "2024-10-30", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04938466" }, { "nct_id": "NCT05304962", "title": "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "RGT-419B", "type": "DRUG" }, { "name": "RGT-419B in combination with hormonal therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regor Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2022-03-04", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • Port Saint Lucie, Florida + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05304962" }, { "nct_id": "NCT03548415", "title": "Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acromegaly" ], "interventions": [ { "name": "IONIS-GHR-LRx", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 43, "start_date": "2018-09-13", "completion_date": "2021-04-02", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03548415" }, { "nct_id": "NCT00571727", "title": "Long-Term Treatment With rhIGF-1 in GHIS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Growth Hormone Insensitivity Syndrome" ], "interventions": [ { "name": "mecasermin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 92, "start_date": "1991-05-20", "completion_date": "2011-12-15", "has_results": true, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571727" }, { "nct_id": "NCT00225758", "title": "Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gary Schwartz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2006-01", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2018-07-27", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 3, "location_summary": "Aurora, Colorado • Lebanon, New Hampshire • Lake Success, New York", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225758" }, { "nct_id": "NCT02580032", "title": "Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Growth Disorder", "Growth Hormone Deficiency in Children" ], "interventions": [ { "name": "No treatment given", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "13 Years", "sex": "ALL", "summary": "4 Years to 13 Years" }, "enrollment_count": 252, "start_date": "2015-10-05", "completion_date": "2018-05-14", "has_results": false, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Margate", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02580032" }, { "nct_id": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PIK3CA Mutation", "HER2- Negative Breast Cancer", "Hormone Receptor Positive Tumor", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer" ], "interventions": [ { "name": "RLY-2608", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-26", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 51, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Duarte, California + 41 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06982521" }, { "nct_id": "NCT03321981", "title": "MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Zenocutuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 105, "start_date": "2018-01-15", "completion_date": "2023-07-26", "has_results": true, "last_update_posted_date": "2024-03-07", "last_synced_at": "2026-06-27T07:40:40.089Z", "location_count": 3, "location_summary": "Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321981" } ] }